Cal-Maine's $60M investment will boost cage-free egg capacity in 2025, with more to follow as demand and regulations reshape the U.S. egg industry.

MGIC Investment gains from new business, solid annual persistency, higher level of home sales, effective capital deployment and sufficient liquidity.

Fed Chair Powell addresses the Senate today, and Micron reports earnings after today's closing bell.

General Mills Inc (NYSE:GIS, ETR:GRM) on Wednesday forecast a steeper-than-expected drop in full-year profit, citing weaker demand for snacks and refrigerated baked goods, along with rising costs and tariff pressures that are expected to weigh on margins. The Cheerios maker said it expects fiscal 2026 adjusted operating income to fall between 10% and 15%, a sharper decline than the 6.5% drop analysts polled by LSEG had estimated.

BOSTON--(BUSINESS WIRE)-- #IBEW103--McDonald Electrical acquires ANJ Electric to expand electrical and telecommunications service capabilities and footprint across Rhode Island.

Yieldmax MSTR Option Income Strategy ETF's headline ~100%+ yield is mostly return of capital, not sustainable income, making the high payout misleading for long-term investors. The MSTY fund's synthetic covered call strategy on MicroStrategy Incorporated stock exposes it to significant downside risk, especially given MSTR's Bitcoin-driven volatility. While MSTY has outperformed peers in total return since inception, this is unlikely to be repeatable due to NAV erosion and unsustainable distributions.

Cites Continued Failure to Perform Fiduciary Duty by GIPR Management and Board of Directors Cites Continued Failure to Perform Fiduciary Duty by GIPR Management and Board of Directors

RKLB accelerates its Electron launch for HawkEye 360, underscoring its agility in a fast-growing satellite market.

Middlesex Water Company is a high-quality, conservative water utility with strong regulatory relationships, low leverage, and a 52-year streak of dividend increases. Valuation has normalized after years of premium pricing, now trading below 24x P/E, offering an attractive entry point versus its historical average and peers. Expected EPS growth is modest (3-5% annually), but the company's safe dividend and resilient business model make it a reliable long-term holding.

GLDD's $1B backlog, higher ROE and discounted valuation give it an edge over ORN in the booming marine buildout.

VEEV's niche focus and strong margins give it an edge over CRM despite its higher valuation and smaller scale.

MMM's Transportation and Electronics segment posts modest growth in Q1, powered by the transportation and aerospace end markets.

It's been a roller coaster year for semiconductor stocks. Many of the biggest names, like NVIDIA Corp. NASDAQ: NVDA, were on a tear heading into the year on plans for a massive data center buildout to support the needs of artificial intelligence (AI).

LOS ANGELES, June 25, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Silver prices have surged to decade-highs and have nearly doubled in the past five years.

Tesla's new car sales plummeted 27.9% in May from the year before, according to data from the European Automobile Manufacturers Association.

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Neratinib's combination with trastuzumab deruxtecan shows intriguing signals, especially in pancreatic cancer, but pivotal data won't arrive until 2026. Alisertib's phase 2 trials in breast and lung cancer are ongoing, but lack of recent data keeps its potential speculative for now.

Paychex (PAYX) was the worst-performing stock in the S&P 500 Wednesday after the payroll and human resources services provider missed sales estimates as most of its gains came from its acquisition of human capital management software maker Paycor.

BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.